CSL. has filed a patent for multicistronic RNA vaccines, including conventional mRNA and self-replicating RNA vaccines. The claim outlines the structure of the self-replicating RNA, with specific sequences encoding antigens linked to promoters and regulatory elements. GlobalData’s report on CSL gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights CSL Ltd - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on CSL, Personalized cancer vaccines was a key innovation area identified from patents. CSL's grant share as of January 2024 was 47%. Grant share is based on the ratio of number of grants to total number of patents.

Multicistronic self-replicating rna vaccine with multiple antigens

Source: United States Patent and Trademark Office (USPTO). Credit: CSL Ltd

A patent application (Publication Number: US20240024455A1) discloses a multicistronic self-replicating RNA designed for potential use in immunogenic compositions. The RNA includes sequences encoding antigens from various respiratory viruses, such as influenza, respiratory syncytial virus, and coronaviruses like SARS-CoV-2. These antigens are operably linked to specific regulatory elements like subgenomic promoters and internal ribosome entry sites. The RNA can encode multiple antigens in a single construct, allowing for the development of vaccines targeting different strains or subtypes of viruses. Additionally, the patent application describes the use of lipid nanoparticles, polymeric microparticles, or oil-in-water emulsions as carriers for the RNA in pharmaceutical compositions, enhancing delivery and efficacy.

Furthermore, the patent application outlines methods for treating or preventing respiratory viral infections, including influenza and SARS-CoV-2, by administering the immunogenic compositions containing the self-replicating RNA to subjects. The compositions aim to induce both humoral and cell-mediated immune responses in the recipients. The application also includes details on the construction of recombinant DNA plasmids encoding the self-replicating RNA, providing a comprehensive approach to developing vaccines against a range of respiratory viruses. Overall, the disclosed technology offers a promising avenue for the development of novel vaccines with the potential to address current and emerging respiratory viral threats effectively.

To know more about GlobalData’s detailed insights on CSL, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies